Centene (CNC) Stock Forecast & Price Target

$71.69

+0.20 (+0.28%)

(As of 09:58 AM ET)

Centene - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 13 Analyst Ratings

Sell
0

Hold
7

Buy
6

Based on 13 Wall Street analysts who have issued ratings for Centene in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 7 have given a hold rating, and 6 have given a buy rating for CNC.

Consensus Price Target

$85.58
19.83% Upside

According to the 13 analysts' twelve-month price targets for Centene, the average price target is $85.58. The highest price target for CNC is $97.00, while the lowest price target for CNC is $69.00. The average price target represents a forecasted upside of 19.83% from the current price of $71.69.

Get the Latest News and Ratings for CNC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Centene and its competitors.

CNC Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$85.58	$85.75	$85.14	$83.22
Forecasted Upside	19.83% Upside	21.06% Upside	27.73% Upside	17.45% Upside
Consensus Rating	Hold	Hold	Hold	Hold

CRUSHED: How Biden's Replacement Will Devastate Your 401(k)! (Ad)

Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.

>> Get Your FREE Wealth Protection Guide <<

CNC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CNC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Centene Stock vs. The Competition

Type	Centene	Medical Companies	S&P 500
Consensus Rating Score	2.46	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	19.71% Upside	10,674.29% Upside	8.05% Upside
News Sentiment Rating	Neutral News See Recent CNC News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/1/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00	+20.10%
9/13/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$93.00 ➝ $91.00	+21.24%
9/5/2024	Barclays 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$98.00 ➝ $97.00	+36.10%
8/5/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight	$78.00 ➝ $78.00	+0.41%
8/2/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$82.00 ➝ $87.00	+11.80%
7/31/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$80.00 ➝ $89.00	+14.68%
Get the Latest News and Ratings for CNC and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Centene and its competitors with MarketBeat's FREE daily newsletter.
7/29/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$110.00 ➝ $95.00	+32.37%
7/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$83.00 ➝ $69.00	+6.37%
7/15/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$92.00 ➝ $89.00	+31.50%
7/10/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$85.00 ➝ $80.00	+21.56%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$83.00	+17.76%
12/21/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$72.00 ➝ $79.00	+8.55%
9/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Neutral	$79.00 ➝ $72.00	+17.51%
8/30/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$94.00 ➝ $73.00	+13.28%
7/12/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Peer Perform
7/11/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$80.00 ➝ $76.00	+12.91%
4/26/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$94.00 ➝ $87.00	+25.56%
2/14/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$101.00 ➝ $97.00	+32.73%
2/8/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$97.00 ➝ $74.00	+2.91%
2/8/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$110.00 ➝ $95.00	+33.84%
12/14/2022	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$95.00 ➝ $99.00	+18.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:18 AM ET.

Should I Buy Centene Stock? CNC Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 30, 2024. Please send any questions or comments about these Centene pros and cons to contact@marketbeat.com.

Centene
Bull Case

Here are some ways that investors could benefit from investing in Centene Co.:

Centene Co. has shown consistent growth in institutional investor interest, with notable acquisitions and increased stakes by major players like Quantbot Technologies LP and Edgestream Partners L.P., indicating confidence in the company's future prospects.
Recent analyst reports have provided positive outlooks on Centene Co., with price target upgrades and buy ratings from various financial institutions, suggesting a favorable market sentiment towards the stock.
Despite fluctuations in stock price, Centene Co. has maintained a stable financial position with a manageable debt-to-equity ratio, quick ratio, and current ratio, providing a strong foundation for potential growth and stability.
Centene Co. has a diverse portfolio of healthcare services and insurance offerings, positioning the company well to capitalize on the evolving healthcare landscape and potentially generate sustainable revenue streams.
With an average target price of $85.58 and a consensus rating of "Moderate Buy" from analysts, Centene Co. presents an opportunity for investors to benefit from potential stock price appreciation based on market expectations.

Centene
Bear Case

Investors should be bearish about investing in Centene Co. for these reasons:

Centene Co.'s stock performance has been relatively flat, with minimal movement in share price, indicating potential stagnation in value and limited short-term growth opportunities for investors.
Despite analyst coverage and ratings, the stock has faced downgrades and target price reductions, suggesting uncertainties or challenges in Centene Co.'s business operations or market conditions that could impact future performance.
Ownership concentration by institutional investors, with over 90% of the stock held by this group, may lead to increased volatility or limited influence by individual retail investors on the company's strategic decisions or stock price movements.
Market dynamics and regulatory changes in the healthcare sector could pose risks to Centene Co.'s business model and financial performance, potentially affecting investor returns and overall market sentiment towards the stock.
With trading volumes fluctuating and recent trading slightly below the average volume, liquidity concerns may arise for investors looking to buy or sell Centene Co. shares, impacting the ease of transactions and potential price discovery.

CNC Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Centene is $85.58, with a high forecast of $97.00 and a low forecast of $69.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centene in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CNC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNC, but not buy additional shares or sell existing shares.
: According to analysts, Centene's stock has a predicted upside of 19.38% based on their 12-month stock forecasts.
: Over the previous 90 days, Centene's stock had 1 downgrade by analysts.
: Centene has been rated by research analysts at Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, JPMorgan Chase & Co., Oppenheimer, Stephens, TD Cowen, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Centene less than other "medical" companies. The consensus rating for Centene is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CNC compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

The most important AI company you've never heard of (Ad)

Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.

Get the full story on this secret AI company poised for massive growth

This page (NYSE:CNC) was last updated on 10/8/2024 by MarketBeat.com Staff

From Our Partners